Role of Epidemic Tumor Vaccine in Cold Tumors to Hot Tumors
DOI:
https://doi.org/10.54097/1p0ss824Keywords:
Small cell lung cancer; DLL3; CD3; bispecific antibody; Tarlatamab.Abstract
Small cell lung cancer (SCLC) is a type of highly aggressive, prone to early metastasis and recurrence, neuroendocrine malignant tumor. The treatment effect of second-line therapy for patients with recurrence/refractory cases is limited, and new therapeutic targets and strategies are urgently needed. Delta-like ligand 3 (DLL3) is abnormally highly expressed on the surface of most SCLC cells, while its expression is limited in normal tissues, making it a promising therapeutic target. The DLL3/CD3 bispecific antibody can redirect T cells to the vicinity of the tumor, inducing the formation of immune synapses, T cell activation, and tumor cell lysis. Tarlatamab, as the first bispecific antibody targeting DLL3/CD3 to enter clinical trials and obtain regulatory approval, has completed the transformation from preclinical validation to key clinical studies. Studies have shown that tarlatamab has durable anti-tumor activity and manageable safety in patients with recurrent/refractory SCLC. This article reviews the biological basis of DLL3, the mechanism of action of DLL3/CD3 bispecific antibodies, as well as the preclinical and clinical research progress of tarlatamab, and assesses its efficacy and safety in heavily treated SCLC. Overall, DLL3/CD3 bispecific antibodies provide a new immunotherapy pathway for recurrent/refractory SCLC, achieving significant clinical relief and survival improvement. Future research needs to further optimize toxicity management, analyze resistance mechanisms, and screen for advantageous populations to promote its precise and sustainable clinical application.
Downloads
References
[1] Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 3.
[2] von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer[J]. J Clin Oncol, 1999, 17(2): 658-667.
[3] Trigo J, Subbiah V, Besse B, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial[J]. Lancet Oncol, 2020, 21(5): 645-654.
[4] George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer[J]. Nature, 2015, 524(7563): 47-53.
[5] Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo[J]. Sci Transl Med, 2015, 7(302): 302ra136.
[6] Tanaka K, Isse K, Fujihira T, et al. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer[J]. Lung Cancer, 2018, 115: 116-120.
[7] Morgensztern D, Besse B, Greillier L, et al. Efficacy and safety of rovalpituzumab tesirine in third line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study[J]. Clin Cancer Res, 2019, 25(23): 6958-6966.
[8] Blackhall F, Jao K, Greillier L, et al. Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High SCLC: Results from the Phase 3 TAHOE Study[J]. J Thorac Oncol, 2021, 16(9): 1547-1558.
[9] Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer[J]. Clin Cancer Res, 2021, 27(5): 1526-1537.
[10] Paz-Ares L, Champiat S, Lai WV, et al. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study[J]. J Clin Oncol, 2023, 41(16): 2893-2903.
[11] Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer[J]. N Engl J Med, 2023, 389(22): 2063-2075.
[12] Dowlati A, Hummel HD, Champiat S, et al. Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update[J]. J Clin Oncol, 2024, 42(29): 3392-3399.
[13] Mountzios G, Sun L, Cho BC, et al. Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy[J]. N Engl J Med, 2025, 393(4): 349-361.
[14] U.S. Food and Drug Administration. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer [EB/OL]. 2024-05-16.
[15] U.S. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer [EB/OL]. 2025-11-19.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
